I think when LL is approved, if specifically for c

I think when LL is approved, if specifically for covid-19, based on positive mortality results from cd 12, I personally believe that the production numbers for next year can be increased if not restricted by fda guidelines/rules/mandate. I'm not intimately familiar with the mAb production of LL, but i have read that the process efficiency has been dramatically streamlined such that companies "advertise" that "The time from discovery to proof-of-concept trials could be reduced to 5–6 months from a traditional timeline of 10–12 months." (Kelley, B. Developing therapeutic monoclonal antibodies at pandemic pace. Nat Biotechnol 38, 540–545 (2020). https://doi.org/10.1038/s41587-020-0512-5). As i said I'm not sufficiently trained nor qualified to say for sure what pace LL could be produced but if it is the "game changer" we think it is, it seems that there are companies ready, willing and able to start production immediately. (I also realize that even 2000 L of LL might yield only 1500 treatments but i would think some of the bigger companies could and will ramp up as much as possible (ala stop the presses" . Fingers crossed